The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -53,458 | -59,450 | -56,755 | -120,723 |
| Stock-based compensation | 7,405 | 7,407 | 5,980 | 16,489 |
| Non-cash operating lease expense | 59 | 57 | 58 | 1,777 |
| Depreciation and amortization | 8 | 9 | 23 | 176 |
| Net accretion of investments in marketable securities | 0 | 137 | 612 | 2,185 |
| Impairment of held for sale assets | - | 217 | 0 | 378 |
| Gain on disposal of property and equipment | 71 | 15 | - | -62 |
| Amortization of debt issuance costs and accretion of final payment fee | 418 | 492 | - | - |
| Non-cash interest expense and amortization of debt issuance costs | - | - | 213 | 303 |
| Amortization and write-off of deferred debt issuance costs | - | 717 | - | - |
| Other noncash expenses | - | -7 | 39 | - |
| Prepaid expenses and other current assets | -1,644 | 3,555 | 326 | -1,111 |
| Accounts payable | 1,678 | 2,830 | -96 | -2,663 |
| Other assets | - | 0 | -1 | 54 |
| Accrued liabilities | -4,020 | 3,980 | 4,865 | -4,650 |
| Operating lease liabilities | -67 | -46 | 39 | -1,873 |
| Net cash used in operating activities | -46,404 | -47,955 | -46,633 | -111,852 |
| Purchases of marketable securities | 0 | 0 | 0 | 82,868 |
| Cash paid for acquisition of assets | - | 0 | 0 | 0 |
| Proceeds from maturities of marketable securities | 0 | 42,583 | 51,246 | 157,341 |
| Proceeds from sale of property and equipment | 71 | 47 | 87 | 84 |
| Purchases of property and equipment | - | - | 16 | - |
| Net cash provided by investing activities | 71 | 42,646 | 51,317 | 74,557 |
| Proceeds from term loan, net | - | 38,899 | -136 | 18,398 |
| Proceeds from exercise of stock options | - | 0 | 0 | 0 |
| Proceeds from employee stock purchase plan purchases | - | 216 | 0 | 59 |
| Payments for offering costs in connection with at-the-market offering and initial public offering | - | - | 0 | - |
| Proceeds from issuance of common stock in at-the-market transactions, net of commission and offering costs | 10,875 | 19,653 | - | - |
| Net cash provided by financing activities | 10,875 | 58,768 | -136 | 18,457 |
| Net change in cash and cash equivalents and restricted cash | -35,458 | 53,459 | 4,548 | -18,838 |
| Cash and cash equivalents and restricted cash at beginning of year | 182,530 | 129,071 | 143,361 | - |
| Cash and cash equivalents and restricted cash at end of period | 147,072 | 182,530 | 129,071 | - |
Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics, Inc. (NMRA)